ヨーロッパのバイオシミラー(バイオ後続品)市場及び製品パイプライン分析

◆英語タイトル:Europe Biosimilars Market & Pipeline Insight
◆商品コード:KUICK4102202
◆発行会社(調査会社):KuicK Research
◆発行日:2014年10月
◆ページ数:360
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆産業分野:医療
◆販売価格オプション(消費税別)
Single user(1名使用)USD2,400 ⇒換算¥264,000見積依頼/購入/質問フォーム
Multi User(社内共有可)USD4,800 ⇒換算¥528,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research 社の日本における正規販売代理店です。KuicK Research 社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time.

One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June’2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February’2015.

The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules.

Currently there are 18 biosimilars available in European market and more than 90 are in multiple phases of development in clinical pipeline. Majority of the available biosimilars are approved for the treatment of indication like Cancer, Kidney Failure and Anemia. Approved Biosimilars in Europe:

Abseamed (epoetin alfa), Bemfola (follitropin alfa), Binocrit (epoetin alfa), Biograstim (filgrastim), Epoetin Alfa Hexal (epoetin alfa), Filgrastim Hexal (filgrastim), Grastofil (filgrastim), Inflectra (infliximab), Nivestim (filgrastim), Omnitrope (somatropin), Ovaleap (follitropin alfa), Ratiograstim (filgrastim), Remsima (infliximab), Retacrit (epoetin zeta), Silapo (epoetin zeta), Tevagrastim (filgrastim), Zarzio (filgrastim), Wepox (epoetin alfa)

“Europe Biosimilars Market & Pipeline Insight” Report Highlight:

• Biosimilars Market Overview & Trend Analysis by Country
• Biosimilars Introduction Timeline in Europe
• Biosimilars Development & Market Authorization Guidelines
• Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
• Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country
• Europe Biosimilars Pipeline: 93 Biosimilars
• Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine)

【レポートの目次】

1. Europe Biosimilars Market Overview
1.1 Current Market Scenario
1.2 Biosimilars Clinical Pipeline Overview

2. Europe Biosimilars Market Trend Analysis by Country
2.1 Austria
2.2 Belgium
2.3 France
2.4 Germany
2.5 Hungary
2.6 Italy
2.7 Norway
2.8 Poland
2.9 Spain
2.10 Sweden
2.11 Switzerland
2.12 UK

3. Biosimilars Introduction Timeline in Europe
3.1 Growth Hormones in 2006
3.2 Epoetin in 2007
3.3 G-CSF in 2008
3.4 Monoclonal Antibodies in 2013
3.5 Follitropin in 2013
3.6 Insulin in 2015

4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario

5. Europe Biosimilars Market Dynamics
5.1 Favorable Market Parameters
5.1.1 Bolar Provisions Supporting Biosimilars Development
5.1.2 Patent Expiry to Tap European Biosimilars Markets
5.1.3 Reimbursement Policies
5.1.4 Increasing Level of Investments
5.1.5 Manufacturing Capabilities
5.1.6 R&D Expertise
5.2 Market Growth Challenges

6. Future Prospectus of Biosimilars in Europe

7. Regulatory & Approval Authorities: EMA & CHMP

8. Biosimilars Development & Market Authorization Guidelines
8.1 Development of Similar Biological Medicinal Products Containing r-hFSH
8.2 Similar Biological Medicinal Products Containing Interferon Beta
8.3 Immunogenicity Assessment of Monoclonal Antibodies Intended For In Vivo Clinical Use
8.4 Similar Biological Medicinal Products Containing Monoclonal Antibodies
8.5 Similar Biological Medicinal Products Containing Recombinant Erythropoietins
8.6 Similar Medicinal Products Containing Recombinant Human Soluble Insulin
8.7 Similar Medicinal Products Containing Somatropin
8.8 Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance
8.9 Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
8.10 Comparability of Biotechnology-Derived Medicinal Products After A Change In The Manufacturing Process

9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country
9.1 Unknown
9.2 Research
9.3 Preclinical
9.4 Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-III
9.9 Preregistration
9.10 Registered

10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country

11. No Development Reported in Biosimilars Clinical Pipeline
11.1 No Development Reported
11.2 Discontinued

12. Competitive Landscape
12.1 Apotex
12.2 Celltrion Healthcare
12.3 Hexal
12.4 Hospira
12.5 Finox Biotech
12.6 Medice Arzneimittel Pütter
12.7 Sandoz
12.8 Stada Arzneimittel
12.9 Teva Pharma

Figure 1-1: Europe – Biosimilars Market Opportunity (US$ Million), 2014-2020
Figure 1-2: Factors Responsible for Growth of Biosimilars Market in Europe
Figure 1-3: Europe Biosimilar Pipeline by Phase (%), 2014
Figure 1-4: Europe Biosimilar Pipeline by Phase (Number), 2014
Figure 1-5: No Development Reported in Biosimilar Pipeline by Phase (%), 2014
Figure 1-6: No Development Reported in Biosimilar Pipeline by Phase (Number), 2014
Figure 1-7: Suspended Biosimilar Pipeline by Phase (%), 2014
Figure 1-8: Suspended Biosimilar Pipeline by Phase (%), 2014
Figure 3-1 Biosimilar Product Approval Timeline in Europe
Figure 3-2: Europe Biosimilars Market Emerging Segment
Figure 3-3: Approved Biosimilars by Segment
Figure 3-4: HGH Biosimilars Approved & Available in European Market
Figure 3-5: EPO Biosimilars Approved & Available in European Market
Figure 3-6: G-CSF Biosimilars Approved & Available in European Market
Figure 3-7: mAbs Biosimilars Approved & Available in European Market
Figure 3-8: Follitropin Biosimilars Approved & Available in European Market
Figure 3-9: Insulin Biosimilars Approved & Available in European Market
Figure 4-1: Safety Evaluation of Biosimilars after Marketing Approval in Europe
Figure 4-2: Risk Management of Biosimilars
Figure 4-3: Overview of Demonstrating Biosimilarity
Figure 5-1: Bolar Provision for the Development of Biosimilars in Europe
Figure 5-2: Effects of Reimbursement Policies on Healthcare System
Figure 5-3: Available Biosimilars in Market by Company & Segment
Figure 5-4: Drivers for Success in European Biosimilars Market
Figure 5-5: Market Growth Challenges
Figure 7-1: Regulatory Timeline for the Approval of Biosimilars
Figure 7-2: Schematic Overview of Biosimilar Approval in EU
Figure 7-3: Biosimilars Development Process



【掲載企業】

Apotex, Celltrion Healthcare, Hexal, Hospira, Finox Biotech, Medice Arzneimittel Pütter, Sandoz, Stada Arzneimittel, Teva Pharma


★調査レポート[ヨーロッパのバイオシミラー(バイオ後続品)市場及び製品パイプライン分析]販売に関する免責事項
★調査レポート[ヨーロッパのバイオシミラー(バイオ後続品)市場及び製品パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆